Planning a future randomized clinical trial based on a network of relevant past trials

Trials

Volumn 19, Issue 1, 2018, Pages

  Salanti, Georgia ^a   Nikolakopoulou, Adriani ^a   Sutton, Alex J ^b   Reichenbach, Stephan ^a   Trelle, Sven ^a   Naci, Huseyin ^c   Egger, Matthias ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

Conditional power; Evidence synthesis; Historical data; Rheumatoid arthritis; Sample size

Indexed keywords

BIOLOGICAL PRODUCT;

ARTICLE; CLINICAL DECISION MAKING; COMPARATIVE STUDY; CONDITIONAL TRIAL DESIGN; EVIDENCE BASED PRACTICE; MEDICAL DECISION MAKING; METHODOLOGY; MULTIPLE SCLEROSIS; NETWORK META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SAMPLE SIZE; STUDY DESIGN; HUMAN; NETWORK META-ANALYSIS; PROCEDURES;

ARTHRITIS, RHEUMATOID; HUMANS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NETWORK META-ANALYSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SAMPLE SIZE;

EID: 85050031011     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-018-2740-2     Document Type: Article

References (23)

1. Clarke M. Doing new research? Don't forget the old. PLoS Med. 2004;1:e35.
2. Ferreira ML, Herbert RD, Crowther MJ, Verhagen A, Sutton AJ. When is a further clinical trial justified? BMJ. 2012;345:e5913.
3. Goudie AC, Sutton AJ, Jones DR, Donald A. Empirical assessment suggests that existing evidence could be used more fully in designing randomized controlled trials. J Clin Epidemiol. 2010;63:983-91.
4. Cooper NJ, Jones DR, Sutton AJ. The use of systematic reviews when designing studies. Clin Trials Lond Engl. 2005;2:260-4.
5. Clark T, Berger U, Mansmann U. Sample size determinations in original research protocols for randomised clinical trials submitted to UK research ethics committees: review. BMJ. 2013;346:f1135.
6. Jones AP, Conroy E, Williamson PR, Clarke M, Gamble C. The use of systematic reviews in the planning, design and conduct of randomised trials: a retrospective cohort of NIHR HTA funded trials. BMC Med Res Methodol. 2013;13:50.
7. Robinson KA, Goodman SN. A systematic examination of the citation of prior research in reports of randomized, controlled trials. Ann Intern Med. 2011;154:50-5.
8. Petropoulou M, Nikolakopoulou A, Veroniki A-A, Rios P, Vafaei A, Zarin W, et al. Bibliographic study showed improving statistical methodology of network meta-analyses published between 1999 and 2015. J Clin Epidemiol. 2017;82:20-8.
9. Sutton AJ, Cooper NJ, Jones DR, Lambert PC, Thompson JR, Abrams KR. Evidence-based sample size calculations based upon updated meta-analysis. Stat Med. 2007;26:2479-500.
10. Roloff V, Higgins JPT, Sutton AJ. Planning future studies based on the conditional power of a meta-analysis. Stat Med. 2013;32:11-24.
11. Sutton AJ, Cooper NJ, Jones DR. Evidence synthesis as the key to more coherent and efficient research. BMC Med Res Methodol. 2009;9:29.
12. Nikolakopoulou A, Mavridis D, Salanti G. Using conditional power of network meta-analysis (NMA) to inform the design of future clinical trials. Biom J. 2014;56:973-90.
13. Nikolakopoulou A, Mavridis D, Salanti G. Planning future studies based on the precision of network meta-analysis results. Stat Med. 2016;35:978-1000.
14. Siontis GCM, Stefanini GG, Mavridis D, Siontis KC, Alfonso F, Pérez-Vizcayno MJ, et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet. 2015;386:655-64.
15. Hazlewood GS, Barnabe C, Tomlinson G, Marshall D, Devoe D, Bombardier C. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ. 2016;353:i1777.
16. Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial. Arthritis Rheum. 2012;64:2824-35.
17. Scolding N, Barnes D, Cader S, Chataway J, Chaudhuri A, Coles A, et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol. 2015;15:273-9.
18. Tramacere I, Del Giovane C, Salanti G, D'Amico R, Filippini G. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2015;9:CD011381.
19. Longworth L, Youn J, Bojke L, Palmer S, Griffin S, Spackman E, et al. When does NICE recommend the use of health technologies within a programme of evidence development?: a systematic review of NICE guidance. PharmacoEconomics. 2013;31:137-49.
20. Eichler H-G, Thomson A, Eichler I, Schneeweiss S. Assessing the relative efficacy of new drugs: an emerging opportunity. Nat Rev Drug Discov. 2015;14:443-4.
21. Naci H, O'Connor AB. Assessing comparative effectiveness of new drugs before approval using prospective network meta-analyses. J Clin Epidemiol. 2013;66:812-6.
22. Altman DG. The scandal of poor medical research. BMJ. 1994;308:283-4.
23. Kleinert S, Horton R. How should medical science change? Lancet. 2014;383:197-8.